Past and Future Therapy for Hepatitis C
Past and Future Therapy for Hepatitis C
Air date: Wednesday, November 12, 2014, 3:00:00 PM
Category: WALS - Wednesday Afternoon Lectures
Runtime: 00:53:03
Description: Wednesday Afternoon Lecture
Annual Astute Clinician Lecture
The Astute Clinician series honors a U.S. clinician-scientist who has observed an unusual clinical occurrence, and by investigating it, has opened an important new avenue of research. Dr. Jay H. Hoofnagle, an expert in liver diseases, has been involved in early evaluation and development of virtually all antiviral agents developed for viral hepatitis including interferon, ribavirin, lamivudine and adefovir dipivoxil.
He has studied Hepatitis C, the most critical area of all liver disease research, for over 30 years. Dr. Hoofnagle will discuss the hepatitis C virus, new insights in how it harms the liver, and new developments of new direct acting antivirals that now promise to cure the majority of patients with this very important liver disease.
For more information go to http://wals.od.nih.gov
Author: Jay H. Hoofnagle, M.D., Director, Liver Disease Research Branch, NIDDK, NIH
Permanent link: http://videocast.nih.gov/launch.asp?18731
Видео Past and Future Therapy for Hepatitis C канала NIH VideoCast
Air date: Wednesday, November 12, 2014, 3:00:00 PM
Category: WALS - Wednesday Afternoon Lectures
Runtime: 00:53:03
Description: Wednesday Afternoon Lecture
Annual Astute Clinician Lecture
The Astute Clinician series honors a U.S. clinician-scientist who has observed an unusual clinical occurrence, and by investigating it, has opened an important new avenue of research. Dr. Jay H. Hoofnagle, an expert in liver diseases, has been involved in early evaluation and development of virtually all antiviral agents developed for viral hepatitis including interferon, ribavirin, lamivudine and adefovir dipivoxil.
He has studied Hepatitis C, the most critical area of all liver disease research, for over 30 years. Dr. Hoofnagle will discuss the hepatitis C virus, new insights in how it harms the liver, and new developments of new direct acting antivirals that now promise to cure the majority of patients with this very important liver disease.
For more information go to http://wals.od.nih.gov
Author: Jay H. Hoofnagle, M.D., Director, Liver Disease Research Branch, NIDDK, NIH
Permanent link: http://videocast.nih.gov/launch.asp?18731
Видео Past and Future Therapy for Hepatitis C канала NIH VideoCast
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Toward Personalizing HIV Treatment and Prevention
Gene editing for cure of persistent viral infections
Deep Mutagenesis Analysis of Evolvability in a DNA Polymerase AAA Clamp Loader System
Introducing OpenAlex: an open and complete index of the global research system
Data and Safety Monitoring Committees: Scope of Responsibilities Part 3
What You Need to Know About Interferon Beta (Avonex®, Betaseron®, Extavia®, Rebif®)
Marathons for T Cells: How They Keep on Killing
Neuronal Response to Injury and Stress: Insights from C. elegans
It Might Be Good to Have Herpes | Trained Immunity
Data and Safety Monitoring Committees: Why, What, Who, and How? Part 2
Robin Roth, a baby boomer, was diagnosed with hepatitis C following a routine doctor’s visit
Heterogeneity of Breast Cancer Genomes
Data and Safety Monitoring Committees: Trials Needing DSMBs Part 4
What is randomisation?
Ethical Principles in Clinical Research: Changing Landscape of Clinical Research Part 4
Should Older Adults with Diabetes and Obesity Lose Weight?
3rd de Duve Lecture - D. Sabatini: mTOR and lysosomes in growth control
Career pathways in clinical research
Mitochondria as signaling organelles : control, physiology and pathology
Hepatitis C Virus Releasing Viral RNA